Based on the provided sources, there is no specific information available regarding the testing of lurbinectedin on infants. The sources primarily focus on the drug's patent information, clinical trials, and its use in adults with specific types of cancer.
The first source, Drug Patent Watch, provides information about the patent status of lurbinectedin but does not mention any specific testing on infants [1].
The second source, a research article published in the National Center for Biotechnology Information (NCBI) database, discusses the clinical trials and efficacy of lurbinectedin in adults with small-cell lung cancer and advanced solid tumors [2]. However, it does not mention any studies or trials involving infants.
The third source is the FDA-approved drug label for lurbinectedin, which provides information about the drug's indications, dosage, and safety information for adult patients [3]. It does not mention any specific testing or use in infants.
Based on the available information, it can be concluded that there is no evidence or mention of lurbinectedin being tested on infants in the provided sources. However, it is important to consult with a healthcare professional or refer to additional scientific literature or clinical trials to obtain a more comprehensive understanding of lurbinectedin's use in different patient populations.
Sources:
[1] Drug Patent Watch. (n.d.). Lurbinectedin - Trademark, Owner, Manufacturer, and Sponsors. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] Trigo, J., Subbiah, V., Besse, B., Moreno, V., Lopez, R., Sala, M. A., ... & Tabernero, J. (2021). Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. The Lancet Oncology, 22(1), 102-112. doi: 10.1016/S1470-2045(20)30556-5
[3] U.S. Food and Drug Administration. (2020). FDA Approved Drug Products: Zepzelca (lurbinectedin) injection, for intravenous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf